New study tests antacid for Post-PPI acid rebound relief
NCT ID NCT07291700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study in Germany looks at whether hydrotalcite (Talcid) can ease acid-related symptoms like heartburn that occur when people stop long-term use of proton pump inhibitors (PPIs). About 167 adults who recently stopped PPIs will take hydrotalcite as needed for four weeks and report their symptom relief and satisfaction. The goal is to see if this antacid helps people avoid restarting PPIs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydrotalcite (Talcid chewable tablet)
What this could lead to
If successful, this could show that hydrotalcite is an effective on-demand option for managing acid rebound symptoms after stopping PPIs, helping people avoid restarting long-term acid suppression.
What could go wrong
This is a small observational study (167 participants) with no control group, so results may not prove cause and effect. The 40% dropout rate could also limit the reliability of findings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bayer Germany
NOT_YET_RECRUITINGWuppertal, 42096, Germany
-
Bayer Vital GmbH
RECRUITINGLeverkusen, 51373, Germany